
Immuneel Just Raised ₹100 Crore. The Bigger Story Is India's Ambition To Build The Future Of Cancer Treatment.
Immuneel Therapeutics' ₹100 crore Series B round highlights growing investor confidence in India's ability to develop advanced cell and gene therapies rather than simply manufacture healthcare products.









